Latest Hotspot

Ractigen Therapeutics Progresses to Clinical Trials with Innovative saRNA Medication, RAG-01

15 December 2023
3 min read

Ractigen Therapeutics, a frontrunner in small activating RNA (saRNA) therapeutic development, is pleased to disclose the lodgment of a clinical trial application within Australia. This submission lays the groundwork for initiating a phase I, open-label, multicentric clinical investigation focused on assessing the safety profile, tolerability, pharmacokinetic behaviors, and initial effectiveness of its pioneering saRNA pharmaceutical, RAG-01, specifically in individuals diagnosed with non-muscle-invasive bladder cancer who have shown resistance to previous Bacillus Calmette-Guérin treatments.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Globally acknowledged as the second saRNA therapeutic to begin human trials, RAG-01 sets a precedent as the foremost in China to reach this crucial stage. This progress denotes a substantial leap in the field of RNA-focused medical treatments, with a noteworthy impact on the difficult arena of oncologic care.

Commenting on this pivotal achievement, Dr. Long-Cheng Li, the founder and guiding force behind Ractigen Therapeutics, conveyed his optimistic perspective: "To us, this milestone transcends a mere formality; it embodies a vital leap forward in utilizing RNAa methodologies in a clinical environment. Our own RNAa framework has been exemplified by the creation of RAG-01, which has demonstrated hopeful efficacy in preclinical oncology models and a robust safety record. 

We are steadfast in our conviction of RAG-01's capability to propel the management of bladder cancer forward, and we are intent on continuing our mission to introduce more groundbreaking saRNA entities into clinical trials, aiming at illnesses that have notoriously been resistant to intervention.”

RAG-01 emerges as an innovative saRNA agent developed by Ractigen Therapeutics, formulated to specifically target and stimulate the p21 tumor suppressor gene. Administered via intravesical route with the state-of-the-art LiCO™ platform by Ractigen, the agent has exhibited pronounced effectiveness in diminishing tumor presence in murine orthotopic models of bladder cancer. Its advancement signifies a significant leap in the quest for RNA-driven therapeutic solutions, aiming to cater to the previously unaddressed medical needs of NMIBC patients.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of December 15, 2023, there are 7 investigational drugs for the PAK4 target, including 9 indications, 7 R&D institutions involved, with related clinical trials reaching 5, and as many as 639 patents.

RAG-01 shows potential as a treatment for non-muscle invasive bladder neoplasms, specifically bladder cancer. The targeting of PAK4 with saRNA technology suggests a novel approach to addressing this disease. However, further research and clinical trials are needed to determine the drug's safety and efficacy in humans.

图形用户界面, 文本, 应用程序

描述已自动生成

What are soft drugs?
"What" Series
2 min read
What are soft drugs?
15 December 2023
Soft drugs are pharmaceuticals that are easily metabolized and inactivated.
Read →
FDA approves Century Therapeutics' CNTY-101 for systemic lupus erythematosus treatment
Latest Hotspot
4 min read
FDA approves Century Therapeutics' CNTY-101 for systemic lupus erythematosus treatment
15 December 2023
Century Therapeutics, a leader in iPSC-derived cell therapies for cancer and autoimmune diseases, announced FDA approval for their Phase 1 trial evaluating CNTY-101 in moderately to severely affected lupus patients unresponsive to at least two standard immunosuppressants.
Read →
Deciphering NTRK Inhibitors and Keeping Up with Their Recent Developments
Deciphering NTRK Inhibitors and Keeping Up with Their Recent Developments
14 December 2023
NTRK fusion is a driving factor in various adult and pediatric cancers, especially in certain rare tumors like infantile fibrosarcoma and secretory breast cancer, where it is highly enriched. Therefore, the future application prospects of NTRK inhibitors in this area are very promising.
Read →
Cocrystal Pharma has begun enrolling the first participant in a Phase 2a trial to evaluate oral CC-42344's efficacy against pandemic and seasonal influenza A
Latest Hotspot
3 min read
Cocrystal Pharma has begun enrolling the first participant in a Phase 2a trial to evaluate oral CC-42344's efficacy against pandemic and seasonal influenza A
14 December 2023
Cocrystal Pharma has initiated the enrollment of the first participant in a Phase 2a clinical trial aimed at assessing the efficacy of the orally-administered CC-42344 for both pandemic and seasonal influenza A strains.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.